Medical Device Injection Molding: Regulatory and Quality Standards

Since February 2, 2026, the FDA’s device manufacturing rule, 21 CFR Part 820, has been the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. For an injection molder, the first question is whether it makes finished devices or components: Part 820 applies to manufacturers of finished devices, while component makers are outside its direct scope and meet medical requirements through their customers’ purchasing controls, quality agreements, and audits. ISO 13485 certification is something customers can require by contract; the FDA neither requires nor issues it.

This article explains the framework for molders and buyers. It is general information, not regulatory advice; device classification, submissions, and compliance decisions belong to the device manufacturer and its regulatory staff.

The U.S. Framework After February 2, 2026

The FDA’s QMSR FAQ states that the revised Part 820 “is now titled the Quality Management System Regulation (QMSR), effective February 2, 2026.” It adds that the rule amends Part 820 “by incorporating by reference the quality management system requirements” of ISO 13485:2016 (FDA QMSR frequently asked questions). The FDA describes the ISO 13485 requirements as “substantially similar” to the old Quality System (QS) regulation when taken in totality, and has added FDA-specific requirements on top of the standard.

Several practical changes follow from the same FAQ:

• Inspections. On February 2, 2026, the FDA stopped using the Quality System Inspection Technique (QSIT) and began using the process in Compliance Program 7382.850.
• Records previously shielded. Management review, quality audit, and supplier audit reports, which the old § 820.180(c) exempted from FDA review, can now be inspected. The FAQ states that those exceptions “are not maintained in the QMSR.”
• Older records. Investigators may review records created before February 2, 2026; the FDA suggests manufacturers may find a comparative analysis useful to show how earlier records meet the QMSR.
• Certificates. In the FAQ’s words, “The FDA will not require certificates of conformance to ISO 13485 and will not issue certificates of conformance to ISO 13485.” A certificate does not exempt a manufacturer from inspection.

The regulation itself is built around the standard. Section 820.10 requires a manufacturer to “Document a quality management system that complies with the applicable requirements of ISO 13485” and to meet FDA requirements such as unique device identification (Part 830), complaint reporting (Part 803), and corrections and removals (Part 806) (21 CFR 820.10 on LII). Section 820.35 adds FDA-specific content to ISO 13485’s records clause for complaints, servicing, and UDI (21 CFR 820.35 on LII). The definitions in § 820.3 refer to the “medical device file (MDF)”, the ISO 13485 term, so teams used to the QS regulation’s design history file, device master record, and device history record should expect their customers to map those records to ISO 13485’s structure.

Component Molder or Finished Device Manufacturer

The scope section answers the question that matters most to a custom molder. Section 820.1(a)(2) reads: “The provisions of this part do not apply to manufacturers of components or parts of finished devices, but such manufacturers are encouraged to consider provisions of this regulation as appropriate” (21 CFR 820.1 on LII). The same regulation defines a component as any “raw material, substance, piece, part, software, firmware, labeling, or assembly that is intended to be included as part of the finished, packaged, and labeled device” (21 CFR 820.3).

That does not mean a component molder escapes medical requirements. It means the requirements arrive through the customer:

Where a given job falls depends on the facts of that job, and the device owner’s regulatory staff should confirm it in writing. A molder that is unsure which row it sits in should not describe itself as “FDA compliant” or “FDA certified”; the FDA does not certify facilities that way.

ISO 13485 Certification: Contract Requirement, Not Legal Prerequisite

Device makers can require suppliers of critical components to hold ISO 13485 certification from an accredited registrar. That is a commercial requirement written into supplier approval and quality agreements. It is not an FDA prerequisite, as the FAQ states. A buyer evaluating a molder should therefore ask two separate questions: does the molder hold the certification the buyer’s own procedures require, and does the molder’s actual practice (validation, change control, traceability, CAPA) meet the quality agreement? A certificate answers the first, an audit answers the second. The audit side of that evaluation is covered in how to evaluate injection molding partners.

The European Union

Devices placed on the EU market fall under the Medical Device Regulation, Regulation (EU) 2017/745. Whether a notified body is involved, and how deeply, depends on the device’s risk class and the conformity assessment route the manufacturer chooses. For a component molder, the EU requirements again arrive mainly through the device manufacturer’s supplier controls; the molder’s job is to supply the documentation and change notifications the manufacturer’s technical file needs.

Materials and Biological Evaluation

Biocompatibility is evaluated for the device, not for a resin in isolation. The FDA’s guidance on ISO 10993-1, issued in September 2023, is titled “Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process” and is written to support PMAs, HDEs, IDEs, 510(k)s, and De Novo requests (FDA guidance on ISO 10993-1). The evaluation is built from the nature and duration of body contact and the risks of the finished device, which includes the effects of molding, additives, colorants, cleaning, and sterilization on the material.

For the molder, that has three consequences:

1. A “medical grade” resin is a starting point. A supplier’s biocompatibility data on a resin does not transfer automatically to a molded, colored, sterilized part.
2. Material changes are design changes. Substituting an “equivalent” grade, a different colorant, a new mold release, or a new regrind ratio can invalidate the device maker’s evaluation. Quality agreements prohibit unapproved substitutions for that reason.
3. Lot traceability is a deliverable. Resin lot numbers, certificates of analysis, and colorant lots have to be linked to molded lots so that the device maker can trace a material issue to affected devices.

Sterilization method is chosen by the device maker and has to be validated with the material. Radiation, ethylene oxide, and steam each affect plastics differently, so the method belongs in the design discussion before the material is locked.

Process Validation in Practice

Internal stresses, voids, and material degradation are not visible on a finished part, so inspecting parts cannot by itself show that a molding process produces conforming parts every time. Device makers therefore treat molding as a process to be validated within their quality systems, and that requirement reaches the molder through the quality agreement. A familiar structure for molding validation is:

• IQ (installation qualification): the press, mold, auxiliaries, and inspection equipment are installed and documented as specified.
• OQ (operational qualification): the process window is explored, for example with a designed experiment, to show which settings matter and the range within which parts conform.
• PQ (performance qualification): production runs at nominal settings, across material lots and shifts, show the process repeatedly produces conforming parts.

The protocol, sample sizes, and acceptance criteria (such as a minimum capability index on critical dimensions) are set in the validation plan agreed with the device maker, with statistical justification for the sample size. After validation, change control governs every change to the press, mold, material, or settings; the molder evaluates whether a change needs revalidation and notifies the customer as the quality agreement requires. The measurement methods behind these studies are explained in quality control methods and standards for molding.

Controlled Environments

Some medical components are molded in classified cleanrooms (classified under ISO 14644-1), and some in controlled but unclassified areas. The requirement comes from the device maker’s specification and risk assessment, not from molding itself. Where a cleanroom is specified, the quote and the audit both cover gowning, environmental monitoring, pressure differentials, and how parts are packaged and moved out of the controlled area.

A Buyer’s and Molder’s Checklist

1. Establish in writing whether the molder is a component supplier or meets the manufacturer definition for this job.
2. Name the certifications the buyer’s supplier procedures require, separately from the regulatory obligations.
3. Agree the quality agreement: change notification, material substitution rules, record retention, complaint support, and audit rights.
4. Agree the validation plan before the mold is built, including acceptance criteria and sample sizes.
5. Confirm lot traceability from resin and colorant to molded lot and shipment.
6. Confirm the sterilization method and its material validation before the resin is locked.

For a molder, the regulatory status of each job, not the label “medical molder,” decides which of these obligations it carries directly and which it carries for its customer.